1. Emerging Horizons in Ovarian Cancer Exploiting Pathways of Susceptibility

2. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

3. FDA-Approved Drugs for Ovarian Cancer

4. FDA-Approved PARP Inhibitors

5. Cellular DNA Repair Pathways

6. PARP Trapping

7. Phase 3 PARP Inhibitor Maintenance Studies

8. SOLO2/ENGOT-OV21: Olaparib vs Placebo as Maintenance Therapy After Platinum-Based Treatment, Phase 3

9. ENGOT-OV16/NOVA: Niraparib vs Placebo as Maintenance Therapy After Platinum-Based Treatment, Phase 3

10. ARIEL3: Rucaparib vs Placebo as Maintenance Therapy After Platinum-Based Treatment, Phase 3

11. Quality-Associated PFS With Olaparib, SOLO2

12. Time Without Symptoms of Disease or Toxicity (TWiST)

13. Mechanisms of Resistance to PARP Inhibitors

14. Enhancing Anti-Tumor Activity Combining PARPi’s with Other Targeted Therapies

15. Potential Overlap of DNA Repair and Angiogenic Pathways

16. PARPi Plus Anti-Angiogenic Therapy Olaparib + Cediranib, Phase 2

17. PARPi Plus Anti-Angiogenic Therapy Olaparib + Cediranib, Ongoing Studies

18. PARPi Plus Anti-Angiogenic Therapy Niraparib + Bevacizumab

19. PARPi Plus Checkpoint Inhibitors Durvalumab + Olaparib or Cediranib, Phase 1

20. PARPi Plus Checkpoint Inhibitors Niraparib + Pembrolizumab, Ongoing Phase 1/2

21. PARPi Plus Checkpoint Inhibitors Ongoing Clinical Trials

22. Other Combination Therapy

23. PARPi Plus Chemotherapy Veliparib + Carboplatin/Paclitaxel, Ongoing Phase 3

24. Key Takeaways

25. Abbreviations

26. Abbreviations (cont)

27. Abbreviations (cont)

28. Abbreviations (cont)